Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to $7.0 million.

  • Journey Medical's Cash from Financing Activities rose 2493.88% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year decrease of 16.28%. This contributed to the annual value of $17.0 million for FY2024, which is 453.73% up from last year.
  • Latest data reveals that Journey Medical reported Cash from Financing Activities of $7.0 million as of Q3 2025, which was up 4,165.45% from $165,000 recorded in Q2 2025.
  • Journey Medical's Cash from Financing Activities' 5-year high stood at $31.8 million during Q4 2021, with a 5-year trough of -$13.1 million in Q2 2023.
  • For the 3-year period, Journey Medical's Cash from Financing Activities averaged around $2.1 million, with its median value being $1.6 million (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 11,890.99% in 2023, then spiked by 3,048.08% in 2024.
  • Journey Medical's Cash from Financing Activities (Quarterly) stood at $31.8 million in 2021, then slumped by 97.02% to $948,000 in 2022, then surged by 1,926.37% to $19.2 million in 2023, then crashed by 44.72% to $10.6 million in 2024, then spiked by 2,493.88% to $7.0 million in 2025.
  • Its Cash from Financing Activities stands at $7.0 million for Q3 2025, versus $165,000 for Q2 2025 and $3.6 million for Q1 2025.